


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claims 1-31 (canceled).

Claim 32 (currently amended): A mixture of 108 different peptides, wherein each of said 108 different peptides comprises an amino acid sequence according to the following formula ("Formula II"; SEQ ID NO: 39):



Q T X¹ T V G G Q A S X² Q A S S L T X³ L F S X⁴ G X⁵ K Q N, wherein
X¹ is either H or T;
X² is either H or R;
X³ is either S, G, or R;
X⁴ is either P, L or Q; and
X⁵ is either A, S, or P.

Claim 33 (currently amended): A composition comprising a plurality of different peptides, wherein each of said ~~plurality of different~~ peptides comprises ~~an~~ a different amino acid sequence provided by Formula II (SEQ ID NO: 39):



Q T X¹ T V G G Q S X² Q A S S L T X³ L F S X⁴ G X⁵ K Q N, wherein
X¹ is either H or T;
X² is either H or R;
X³ is either S, G, or R;
X⁴ is either P, L or Q; and
X⁵ is either A, S, or P.

Claim 34 (currently amended): A composition according to claim 33, wherein said composition consists of 2 to about 10 of said different peptides ~~having said amino sequence provided by Formula II (SEQ ID NO: 39).~~

Claim 35 (previously presented): A composition according to claim 33, further comprising at least one peptide selected from the group consisting of:

G31 TTHTVGGSVARQVHSLTGLFSPGPQQK (SEQ ID NO: 6)
F78 QTHTTGGQAGHQAHS�TGLFSPGAKQN (SEQ ID NO: 19)
R9 QTTVVGGQSHTVRGLTSLFSPGASQN (SEQ ID NO: 10)
D6 QTTTTGGQVSHATHGLTGLFSLGPQQK (SEQ ID NO: 3)
M122 QTTTTGGSASHAVSSLTGLFSPGSKQN (SEQ ID NO: 23); and
H1 QTHTTGGVVGHATSGLTSLFSPGPSQK (SEQ ID NO: 20).

Claim 36 (previously presented): A composition according to claim 35, wherein said composition comprises peptides of SEQ ID NOs: 10, 19, 20, and 3 ("MIX1").

Claim 37 (previously presented): A composition according to claim 35, wherein said composition comprises peptides of SEQ ID NOs: 23 and 6 ("MIX2").

Claim 38 (previously presented): A composition according to claim 35, wherein said composition comprises peptides of SEQ ID NOs: 6, 19, 10, 3, 23 and 20 ("MIX3").

Claims 39 (canceled).


Claim 40 (currently amended): A composition according to claim 33 wherein each of said ~~plurality of different~~ peptides consists of said sequence and a hepatitis C virus E2/NS1 protein with the peptide in the HVR1 position.

Claims 41-42 (canceled).

Claim 43 (previously presented): A composition according to claim 33 wherein said composition further comprises a pharmaceutically acceptable excipient.

Claim 44 (previously presented): A composition according to claim 43 wherein said composition further comprises an adjuvant.

Claim 45 (currently amended): A peptide comprising an amino sequence provided by Formula II (SEQ ID NO: 39):



QTX¹TVGGQASX²QASSLT³LFSX⁴GX⁵KQN, wherein

X^1 is either H or T;


X^2 is either H or R;

X² is either H or R;
X³ is either S, G, or R;

X^4 is either P, L or Q; and

X⁵ is either A, S, or P.

Claim 46 (currently amended): A peptide comprising an amino sequence provided by Formula I (SEQ ID NO: 1):


$$\underline{X^1 T X^2 X^3 X^4 G G X^5 X^6 X^7 X^8 X^9 X^{10} X^{11} X^{12} L X^{13} X^{14} L F X^{15} X^{16} G X^{17} X^{18} Q X^{19}}$$

wherein,

X¹ is Q or T,

X^2 is H, T or R,

X^3 is V or T,

X^4 is T or V,

X^5 is S, V or Q.

X^6 is A, Q or V,

X⁷ is A, G or S,

$$\overline{X^8} \text{ is R or H,}$$

X^9 is T, A or Q,

X^{10} is T, A or V.

X¹¹ is S, H or R,
X¹² is G, S or R,
X¹³ is T or V,
X¹⁴ is S, G or R,
X¹⁵ is S or R,
X¹⁶ is P, L, S or Q,
X¹⁷ is A, P or S,
X¹⁸ is S, K or Q, and
X¹⁹ is N or K.

Claim 47 (withdrawn): A peptide according to claim 46 with an amino acid sequence selected from the group consisting of:

- 2.11 QTHTVGGVQGRQAHSLTSLFSPGASQN (SEQ ID NO: 2)
- D6 QTTTTGGQVSHATHGLTGLFSLGPQQK (SEQ ID NO: 3)
- D18 QTHTTGGSSASHQASGLTRLFSQGSPSQN (SEQ ID NO: 4)
- F63 QTHVVGGQQGRQVSSLVSLFSPGASQK (SEQ ID NO: 5)
- G31 TTHTVGGSVARQVHSLTGLFSPGPQQK (SEQ ID NO: 6)
- L13 QTHTVGGSQAHAAHSLTRLFSPGSSQN (SEQ ID NO: 7)
- M69 QTTVVGGSQARAAHGLVSLFSLGSKQN (SEQ ID NO: 8)
- Z61 QTHVVGGVQGRQTSGLVGLFSPGSKQN (SEQ ID NO: 9)
- R9 QTTVVGGSQSHTVRGLTSLFSPGASQN (SEQ ID NO: 10)
- B26 TTTTTGGQAGHQAHSLSLSPGASQK (SEQ ID NO: 11)
- B22 QTHVVGGVQSHQTSGLTSLFSPGASQK (SEQ ID NO: 12)
- B35 QTHTTGGVQGHQTSRLTSLFSPGPSQN (SEQ ID NO: 13)
- D29 TTTVVGGQAAHQTHSLTSLFSPGAKQN (SEQ ID NO: 14)
- D33 TTTTTGGQQSHTVHGLVGLFSPGSKQN (SEQ ID NO: 15)
- E26 QTHTVGGVQAHTVRGLTSLFSPGSSQN (SEQ ID NO: 16)
- F80 QTHTTGGQAGHTASSLTGLFSPGAKQN (SEQ ID NO: 17)
- F19 QTTTVGGVASHQAHSLSLSPGAKQK (SEQ ID NO: 18)
- F78 QTHTTGGQAGHQAHSLSLSPGAKQN (SEQ ID NO: 19)
- H1 QTHTTGGVVGHATSGLTSLFSPGPSQK (SEQ ID NO: 20)
- L76 TTTTVGGQASHQTSSLTGLFSPGSKQN (SEQ ID NO: 21)

B24 TTTTVGGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 37)
M63 QTHTTGGVVSHQTRSLVGLFSPGPQQN (SEQ ID NO: 38)
M27 QTTTTGGVASHAAHRLTSLFSPGPQQK (SEQ ID NO: 22)
M122 QTTTTGGSASHAVSSLTGLFSPGSKQN (SEQ ID NO: 23)
M129 QTTVVGGSAGHTASSLVGLFSPGSKQN (SEQ ID NO: 24)
M119 TTTTVGGQASHTTSSLTGLFSPGSQQN (SEQ ID NO: 25)
R5 QTHTTGGQASHQVSSLVSLFSPGAKQK (SEQ ID NO: 26)
R6 TTTTGGQVGHQTSGLTGLFSPGAQQN (SEQ ID NO: 27)
R27 TTHVVGGSASHAVRGLTSLFSPGSSQN (SEQ ID NO: 28)

Claim 48 (withdrawn): A peptide of any of the following amino acid sequences:

B14 QTTVTGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 29)
B33 ATHATGGQAAHSTHSLTSLFSPGASQK (SEQ ID NO: 30)
F81 QTHVTGGSAAHQTGGLTGLFSPGPKQN (SEQ ID NO: 31)
B18 QTTVVGGQASHVSRSLTGLFSPGSSQK (SEQ ID NO: 32)
E19 TTHTGGQQAHTTSRLVSLFSPGASQK (SEQ ID NO: 36)
L72 QTTTAAHTTSGLTGLFSPGAKQN (SEQ ID NO: 33)
D20 QTHVTGVAGRQTSGLVSLFSPGSSQN (SEQ ID NO: 34)
D30 QGGVQGHTTSSLVGLFSPGSQQN (SEQ ID NO: 35)

Claim 49 (withdrawn): A composition including a peptide selected from the group consisting of

a) a peptide obtainable from a library as claimed in claim 1; and
2.11 QTHTVGGVQGRQAHSLSLTFSPGASQN (SEQ ID NO: 2); and
D6 QTTTTGGQVSHATHGLTGLFSLGPQQK (SEQ ID NO: 3); and
D18 QTHTTGGASASHQASGLTRLFSQGSPSQN (SEQ ID NO: 4); and
F63 QTHVVGGQQRQVSSLVSLFSPGASQK (SEQ ID NO: 5); and
G31 TTHTVGGSVARQVHSLTGLFSPGPQQK (SEQ ID NO: 6); and
L13 QTHTVGGSQAHAAHSLTRLFSPGSSQN (SEQ ID NO: 7); and
M69 QTTVVGGSQARAAHGLVSLFSLGSKQN (SEQ ID NO: 8); and

Z61 QTHVVGGVQGRQTSGLVGLFSPGSKQN (SEQ ID NO: 9); and
R9 QTTVVGGQSHTVRGLTSLFSPGASQN (SEQ ID NO: 10); and
B26 TTTTGGQAGHQAHSLSLTFSPGASQK (SEQ ID NO: 11); and
B22 QTHVVGGVQSHQTSGLTSLFSPGASQK (SEQ ID NO: 12); and
B35 QTHTTGGVQGHQTSRLTSLFSPGPSQN (SEQ ID NO: 13); and
D29 TTTVVGGQAAHQTHSLTSLFSPGAKQN (SEQ ID NO: 14); and
D33 TTTTGGQQSHTVHGLVGLFSPGSKQN (SEQ ID NO: 15); and
E26 QTHTVGGVQAHTVRGLTSLFSPGSSQN (SEQ ID NO: 16); and
F80 QTHTTGGQAGHTASSLTGLFSPGAKQN (SEQ ID NO: 17); and
F19 QTTTVGGVASHQAHSLSLTFSPGAKQK (SEQ ID NO: 18); and
F78 QTHTTGGQAGHQAHSLSLTFSPGAKQN (SEQ ID NO: 19); and
H1 QTHTTGGVVGHATSGLTSLFSPGPSQK (SEQ ID NO: 21); and
L76 TTTTVGGQASHQTSSLTGLFSPGSKQN (SEQ ID NO: 37); and
B24 TTTTVGGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 38); and
M63 QTHTTGGVVSHQTRSLVGLFSPGPQQN (SEQ ID NO: 22); and
M27 QTTTGGVASHAAHRLTSLFSPGPQQK (SEQ ID NO: 23); and
M122 QTTTGGSSASHAVSSLTGLFSPGSKQN (SEQ ID NO: 24); and
M129 QTTVVGGSSAGHTASSLVGLFSPGSKQN (SEQ ID NO: 25); and
M119 TTTTVGGQASHTTSSLTGLFSPGSQQN (SEQ ID NO: 26); and
R5 QTHTTGGQASHQVSSLVSLFSPGAKQK (SEQ ID NO: 27); and
R6 TTTTGGQVGHQTSGLTGLFSPGAQQN (SEQ ID NO: 28); and
R27 TTHVVGGSSASHAVRGLTSLFSPGSSQN (SEQ ID NO: 29); and
B14 QTTVTGQASHTTSSLTGLFSPGASQK (SEQ ID NO: 29); and
B33 ATHATGGQAAHSTHSLTSLFSPGASQK (SEQ ID NO: 30); and
F81 QTHVTGGSAAHQTGGLTGLFSPGPKQN (SEQ ID NO: 31); and
B18 QTTVVGGQASHVSRLTGLFSPGSSQK (SEQ ID NO: 32); and
E19 TTHTGGQQAHTTSRLVSLFSPGASQK (SEQ ID NO: 36); and
L72 QTTTAAHTTSGLTGLFSPGAKQN (SEQ ID NO: 33); and
D20 QTHVTGVAGRQTSGLVSLFSPGSSQN (SEQ ID NO: 34); and
D30 QGGVQGHHTTSSLVGLFSPGSQQN (SEQ ID NO: 35).

Claim 50 (withdrawn): A composition including a plurality of peptides according to claim 49.

Claim 51 (withdrawn): A composition according to claim 50 including 2 to about 10 different peptides.

Claim 52 (withdrawn): A composition according to claim 50 wherein one or more of said peptides is in a fusion with additional amino acids.

Claim 53 (withdrawn): A composition according to claim 52 wherein said fusion includes HCV E2/NS1 protein with the peptide in the HVR1 position.

Claim 54 (withdrawn): A composition according to claim 53 wherein said fusion is included in a recombinant HCV.

Claim 55 (withdrawn): A composition according to claim 49 including at least one additional component.

Claim 56 (withdrawn): A composition according to claim 55 wherein said composition includes a pharmaceutically acceptable excipient.

Claim 57 (withdrawn): A composition according to claim 55 wherein said composition includes an adjuvant.

Claims 58-96 (canceled).

Claim 97 (currently amended): The composition of claim 33, wherein each of said different peptides consists of said different amino acid sequence.

Claim 98 (previously presented): The peptide of claim 45, wherein said peptide consists of said amino acid sequence.

Claim 99 (previously presented): The peptide of claim 46, wherein said peptide consists of said amino acid sequence.